Physician profile
Crystal R Eppling
NPI 1528744752
$968.63
in general payments reported to CMS, 2019-2025
8 companies · $619 in 2025
The $619 reported for 2025 was more than what 82% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $349 · 2025: $619.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $635 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $333.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $635.30 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $333.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $530.51 | 2024-2025 | Clariti Contact Lens, Myday Contact Lens |
| Bausch & Lomb Americas INC. | $147.35 | 2024-2025 | Miebo, Xiidra |
| Rxsight INC | $111.11 | 2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Biotissue Holdings INC. | $52.08 | 2024-2025 | |
| Johnson & Johnson Vision Care, INC. | $49.03 | 2024-2025 | |
| Abbvie INC. | $32.73 | 2024 | |
| Dompe US, INC. | $24.76 | 2024 | Oxervate |
| Amgen INC. | $21.06 | 2024 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Eppling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.